INMB — Inmune Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711754 ·
Last close
$1.43
Market Cap
$38.02M
52W High
$1.79
52W Low
$1.09
ADV30
399,096
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,812,000 | -5,407,000 | 25,818,000 | 21,358,000 | 6,194,000 |
| Dec 2025 | 0 | — | -5,474,000 | -5,264,000 | 32,351,000 | 24,751,000 | 8,827,000 |
| Sep 2025 | 0 | — | -7,433,000 | -6,472,000 | 33,358,000 | 27,734,000 | 7,980,000 |
| Jun 2025 | 0 | — | -8,057,000 | -24,458,000 | 37,684,000 | 33,374,000 | 8,817,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,582,000
Investing CF
$-336,000
Financing CF
$27,612,000
CapEx
$-336,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.32
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-209,037,000
Inventory
—
Receivables
$4,541,000
ST Investments
—
EBIT TTM
$-30,869,000
Pretax Income TTM
$-45,933,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
—
Free Cash Flow
$-11,248,000
Enterprise Value
$18,700,624
Total Cash
$21,358,000
Total Debt
$1,510,000
Shares Out
26,585,258
Trailing EPS
$-1.62
Book Value
$0.74
ROE
-168.8%
ROA
-52.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 50,000 | -30,869,000 | -45,933,000 | 32,351,000 | 8,827,000 | — | -22,582,000 |
| Dec 2024 | 14,000 | -42,635,000 | -42,082,000 | 39,562,000 | 7,465,000 | — | -33,361,000 |
| Dec 2023 | 155,000 | -29,741,000 | -30,008,000 | 57,001,000 | 18,862,000 | — | -11,980,000 |
| Dec 2022 | 374,000 | -25,951,000 | -27,299,000 | 81,795,000 | 21,691,000 | — | -22,686,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENZN | Viskase Holdings, Inc. | $38.02M | $5.75 | — |
| TVGN | Tevogen Bio Holdings Inc. | $36.01M | $8.60 | — |
| EVAX | Evaxion A/S | $34.28M | $4.11 | — |
| GRML | Greenland Mines Ltd | $43.65M | $0.36 | — |
| SCLX | Scilex Holding Co | $45.05M | $6.41 | — |
News headlines (Yahoo Finance, 1h cache)
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
2026-05-15 12:00 · Yahoo
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
2026-05-14 12:00 · Yahoo
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
2026-05-13 12:00 · Yahoo
INmune Bio (INMB) Q1 2026 Earnings Transcript
2026-05-08 14:30 · Yahoo
INmune Bio, Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
2026-05-07 20:00 · Yahoo
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
2026-05-05 20:00 · Yahoo
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
2026-04-30 12:00 · Yahoo
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
2026-04-16 12:00 · Yahoo
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely
2026-04-01 11:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.